Anne M. Lachiewicz
YOU?
Author Swipe
View article: A Comparison of Piperacillin-Tazobactam With Conventional Antibiotics for Prophylaxis in Lower Extremity Type III Open Fractures
A Comparison of Piperacillin-Tazobactam With Conventional Antibiotics for Prophylaxis in Lower Extremity Type III Open Fractures Open
View article: P-1874. Impact of Compromised Host AntimicRobial Management Service (CHARMS) on All Cause Readmission in Solid Organ Transplant Patients Discharged on Intravenous Antimicrobials
P-1874. Impact of Compromised Host AntimicRobial Management Service (CHARMS) on All Cause Readmission in Solid Organ Transplant Patients Discharged on Intravenous Antimicrobials Open
Background The Compromised Host AntimicRobial Monitoring Service (CHARMS) was created to support safe, efficient, streamlined care for immunocompromised patients discharged on outpatient parenteral antimicrobial therapy (OPAT). However, ou…
View article: Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM)
Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM) Open
www.clinicaltrials.gov (NCT04593940).
View article: Resource Utilization for COVID-19 Pneumonia in the ACTIV-1 Trial: A Secondary Data Analysis
Resource Utilization for COVID-19 Pneumonia in the ACTIV-1 Trial: A Secondary Data Analysis Open
Background Coronavirus disease 2019 (COVID-19) pneumonia requires considerable healthcare resources. Research Objective Examine if a single dose of infliximab or abatacept, in addition to remdesivir and steroids, decreased resource utiliza…
View article: Exebacase in Addition to Standard-of-Care Antibiotics for <i>Staphylococcus aureus</i> Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)
Exebacase in Addition to Standard-of-Care Antibiotics for <i>Staphylococcus aureus</i> Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT) Open
Background Novel treatments are needed for Staphylococcus aureus bacteremia, particularly for methicillin-resistant S. aureus (MRSA). Exebacase is a first-in-class antistaphylococcal lysin that is rapidly bactericidal and synergizes with a…
View article: 2765. Dalbavancin for challenging left ventricular assist device driveline infections
2765. Dalbavancin for challenging left ventricular assist device driveline infections Open
Background Driveline tract and exit site infections (DLI) in patients on left ventricular assist device (LVAD) support occur frequently and are associated with significant morbidity, mortality and recurrence. Dalbavancin is a gram+ active …
View article: Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia Open
Importance Immune dysregulation contributes to poorer outcomes in COVID-19. Objective To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. Design, Setting, and P…
View article: Utility of Urine Cultures During Febrile Neutropenia Workup in Hematopoietic Stem Cell Transplantation Recipients Without Urinary Symptoms
Utility of Urine Cultures During Febrile Neutropenia Workup in Hematopoietic Stem Cell Transplantation Recipients Without Urinary Symptoms Open
The utility of obtaining screening urine cultures for febrile neutropenia (FN) during hematopoietic stem cell transplant (HCT) is unknown. In 667 adult HCT patients with FN, only 40 (6%) were found with bacteriuria. Antibiotics were modifi…
View article: Liver transplantation from a SARS-COV-2-positive donor: A road ahead or not
Liver transplantation from a SARS-COV-2-positive donor: A road ahead or not Open
View article: Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center
Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center Open
Amidst the therapeutic void at the onset of the COVID-19 pandemic, a critical mass of scientific and clinical interest coalesced around COVID-19 convalescent plasma (CCP). To date, the CCP literature has focused largely on safety and effic…
View article: LB1531A. Administration of abatacept, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial.
LB1531A. Administration of abatacept, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial. Open
Background Severe COVID-19 infection is characterized by a dysregulated hyperinflammatory state that contributes to morbidity and mortality. Immunomodulatory therapy has been shown to improve outcomes. We investigated if abatacept, CTLA-4-…
View article: Eravacycline Associated Hypofibrinogenemia: A Case Series of Transplant Patients With<i>Mycobacterium Abscessus</i>Infections and Review of Literature
Eravacycline Associated Hypofibrinogenemia: A Case Series of Transplant Patients With<i>Mycobacterium Abscessus</i>Infections and Review of Literature Open
View article: Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial Open
Cidara Therapeutics and Mundipharma.
View article: Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19
Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19 Open
Background We investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19. Methods We conducted a master protocol to investigate im…
View article: Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19 Open
Background Immune dysregulation contributes to poorer outcomes in severe Covid-19. Immunomodulators targeting various pathways have improved outcomes. We investigated whether infliximab provides benefit over standard of care. Methods We co…
View article: Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study Open
In this study, in a high-risk population of patients admitted for COVID-19, we found an earlier time to hospital discharge among participants receiving CCP with nAb titers of >1:640 compared with participants receiving CCP with a lower nAb…
View article: Retrospective analysis of multidrug-resistant clinical and environmental isolates for the presence of the colistin-resistance gene <i>mcr-1</i>
Retrospective analysis of multidrug-resistant clinical and environmental isolates for the presence of the colistin-resistance gene <i>mcr-1</i> Open
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
View article: Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study
Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study Open
Background COVID-19 Convalescent Plasma (CCP) was an early and widely adopted putative therapy for severe COVID-19. Results from randomized control trials and observational studies have failed to demonstrate a clear therapeutic role for CC…
View article: Outcomes of Convalescent Plasma with Defined High- Versus Lower-Neutralizing Antibody Titers Against SARS-CoV-2 Among Hospitalized Patients: Coronavirus Inactivating Plasma (CoVIP), Double-Blind Phase 2 Study
Outcomes of Convalescent Plasma with Defined High- Versus Lower-Neutralizing Antibody Titers Against SARS-CoV-2 Among Hospitalized Patients: Coronavirus Inactivating Plasma (CoVIP), Double-Blind Phase 2 Study Open
View article: Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study Open
COVID-19 convalescent plasma (CCP) was an early and widely adopted putative therapy for severe COVID-19. Results from randomized control trials and observational studies have failed to demonstrate a clear therapeutic role for CCP for sever…
View article: Corrigendum to ‘Prosthetic Joint Infection After Dental Work: Is the Correct Prophylaxis Being Prescribed? A Systematic Review’ [Arthroplasty Today 7 (2021) 69-75]
Corrigendum to ‘Prosthetic Joint Infection After Dental Work: Is the Correct Prophylaxis Being Prescribed? A Systematic Review’ [Arthroplasty Today 7 (2021) 69-75] Open
View article: Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19 Open
ClinicalTrials.gov Identifier: NCT04362813.
View article: Prosthetic Joint Infection After Dental Work: Is the Correct Prophylaxis Being Prescribed? A Systematic Review
Prosthetic Joint Infection After Dental Work: Is the Correct Prophylaxis Being Prescribed? A Systematic Review Open
View article: Prioritizing studies of COVID-19 and lessons learned
Prioritizing studies of COVID-19 and lessons learned Open
Introduction: COVID-19 altered research in Clinical and Translational Science Award (CTSA) hubs in an unprecedented manner, leading to adjustments for COVID-19 research. Methods: CTSA members volunteered to conduct a review on the impact o…
View article: Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and <i>Achromobacter xylosoxidans</i> Infections
Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and <i>Achromobacter xylosoxidans</i> Infections Open
Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurr…
View article: Predictors of multi-drug resistance in burn wound colonization following burn injury in a resource-limited setting
Predictors of multi-drug resistance in burn wound colonization following burn injury in a resource-limited setting Open
View article: Emerging Epidemics in Transplant: Histoplasmosis, Blastomycosis, and Paracoccidioidomycosis
Emerging Epidemics in Transplant: Histoplasmosis, Blastomycosis, and Paracoccidioidomycosis Open
The endemic fungi are a group of thermally dimorphic fungi that occupy specific defined environmental ranges. They count Histoplasma, Blastomyces, Paracoccidioides, Coccidioides, Talaromyces, Emergomyces, and Sporothrix among their number.…
View article: Loss of daptomycin susceptibility in clinical Staphylococcus epidermidis infection coincided with variants in WalK
Loss of daptomycin susceptibility in clinical Staphylococcus epidermidis infection coincided with variants in WalK Open
Daptomycin (DAP) is key in treating multidrug-resistant Staphylococcus infections. Diminished susceptibility to DAP is emerging among Staphylococcus epidermidis strains although mechanisms for non-susceptibility (NS) remain poorly understo…
View article: Varicella-zoster virus post-exposure management and prophylaxis: A review
Varicella-zoster virus post-exposure management and prophylaxis: A review Open
Varicella-zoster virus causes both varicella (chickenpox) and herpes zoster (shingles). Although varicella incidence has dramatically declined since introduction of the live-attenuated varicella vaccine, vaccination rates are suboptimal, a…
View article: 730. Cefiderocol for the Treatment of Achromobacter xylosoxidans Infections in Two Lung Transplant Patients with Cystic Fibrosis
730. Cefiderocol for the Treatment of Achromobacter xylosoxidans Infections in Two Lung Transplant Patients with Cystic Fibrosis Open
Background Achromobacter xylosoxidansis a highly resistant Gram-negative bacterium that causes chronic infections in patients with cystic fibrosis (CF). Treatment options for A. xylosoxidans are limited. In the peri-lung transplant setting…